Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies

NCT05443126 is registered in ClinicalTrials.gov with Ellipses Pharma as lead sponsor.

NCT NCT05443126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05443126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies
Lead sponsor
Ellipses Pharma
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 30, 2022
Completion date
March 31, 2028
Enrollment
265 (estimated)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc